Sebetralstat Explained

Legal Status:	Investigational
Cas Number:	1933514-13-6
Pubchem:	121365142
Iuphar Ligand:	11947
Drugbank:	DB18305
Chemspiderid:	115006749
Unii:	O5ZD2TU2B7
Kegg:	D12396
Chembl:	5095248
Synonyms:	KVD-900
Iupac Name:	N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-4-[(2-oxopyridin-1-yl)methyl]phenylmethyl]pyrazole-4-carboxamide| C=26 | H=26 | F=1 | N=5 | O=4| SMILES = COCC1=NN(C=C1C(=O)NCC2=NC=CC(=C2F)OC)CC3=CC=C(C=C3)CN4C=CC=CC4=O| StdInChI = 1S/C26H26FN5O4/c1-35-17-22-20(26(34)29-13-21-25(27)23(36-2)10-11-28-21)16-32(30-22)15-19-8-6-18(7-9-19)14-31-12-4-3-5-24(31)33/h3-12,16H,13-15,17H2,1-2H3,(H,29,34)| StdInChIKey = KGMPDQIYDKKXRD-UHFFFAOYSA-N

Sebetralstat is an investigational new drug that is being evaluated for the treatment of hereditary angioedema.^[1] It is a plasma kallikrein inhibitor.^[2]

Notes and References

1. Web site: Sebetralstat - KalVista Pharmaceuticals . AdisInsight . Springer Nature Switzerland AG .
2. Davie RL, Edwards HJ, Evans DM, Hodgson ST, Stocks MJ, Smith AJ, Rushbrooke LJ, Pethen SJ, Roe MB, Clark DE, McEwan PA, Hampton SL . Sebetralstat (KVD900): A Potent and Selective Small Molecule Plasma Kallikrein Inhibitor Featuring a Novel P1 Group as a Potential Oral On-Demand Treatment for Hereditary Angioedema . Journal of Medicinal Chemistry . 65 . 20 . 13629–13644 . October 2022 . 36251573 . 9620001 . 10.1021/acs.jmedchem.2c00921 .